Status:

WITHDRAWN

Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Coronavirus Disease 2019 (COVID-19)

Pneumonia

Eligibility:

All Genders

18-80 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate safety, tolerability, and pharmacodynamics of frespaciguat after administration of multiple doses to participants with COVID-19 pneumonia. The primary hypothes...

Eligibility Criteria

Inclusion

  • Has virologically confirmed COVID-19 requiring hospital admission.
  • Has respiratory symptoms including cough and dyspnea
  • Requires supplemental oxygen therapy
  • Male participant is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) (example, 5 terminal half-lives after the last dose of study intervention)
  • Female participant is not a woman of childbearing potential (WOCBP) or is a WOCBP who is abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) (example, 5 terminal half-lives after the last dose of study intervention)

Exclusion

  • Has pre-existing medical conditions of any nature which are immediately pre-terminal such as death or limitation of life-sustaining therapy is expected to be imminent
  • Requires or is expected to require invasive mechanical ventilation
  • Requires or is expected to require noninvasive mechanical ventilation
  • Has any issue which would prohibit them from effective use of the frespaciguat inhaler
  • Hypoxemia which is explained by any condition other than COVID-19, example, preexisting cardiac or pulmonary disease
  • Has severe hepatic impairment (meets Child-Pugh Class C criteria)
  • Has severe renal impairment and/or requirement for renal dialysis

Key Trial Info

Start Date :

July 7 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 10 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04425733

Start Date

July 7 2020

End Date

November 10 2020

Last Update

May 15 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.